X

Trial Profile

A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Veltuzumab (Primary)
Indications Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors Gilead Sciences; Immunomedics

Most Recent Events

09 Jan 2014 Status changed from completed to discontinued as reported by M D Anderson Cancer Center record
09 Jan 2014 Planned number of patients changed from 28 to 98 as reported by MD Anderson Cancer Center
02 Feb 2012 Status changed from discontinued to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com